EU/CLN2/0031 March 2017
In young children with severe new-onset seizures/epilepsy:
In children with progressive neurodegeneration, who have be en diagnosed with:
Other progressive pediatric brain disorders should be excluded:1
BioMarin has partnered with Invitae to bring you the Behind the Seizure® program—a no-charge epilepsy gene panel testing program to help you diagnose CLN2 disease early.
In as little as 2 weeks, an epilepsy gene panel test can bring you and your eligible patients closer to identifying if there is a genetic cause behind the seizure.
Visit www.behindtheseizure.com to learn more and to order a test.
Reference: 1. Chang M, Cooper JD, Davidson BL, et al. CLN2. In: Mole S, Williams R, and Goebel H, eds. The neuronal ceroid lipofuscinoses (Batten Disease). 2nd ed. Oxford, United Kingdom: Oxford University Press; 2011:80-109.
Start typing and press Enter to search